BGB-A317-309

Active, not recruiting

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Beigene Study ID info

BGB-A317-309

ClinicalTrials.gov ID info

Clinical Drug Trials ID info

CTR20182534

Study Overview

Sex: All

Age: 18 Years to 75 Years (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years to 75 Years (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

You are now leaving BeiGene Australia


BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL